Helen S. Te, MD

Transplant Hepatology
Graduated From: 
University of the Philippines, Manila, Philippines
Current Position: 
Medical Director, Adult Liver Transplantation, University of Chicago Medicine; Associate Professor of Medicine, University of Chicago Medicine
Current Projects: 
The effect of chronic rifaximin use in the incidence and severity of acute kidney injury in patients with cirrhosis Autoimmune hepatitis – beyond standard therapy A Multicenter, Double-Blind, Sponsor-Open Trial of IDN-6556 in Subjects Who had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following anti-HCV Therapy. Recurrent hepatitis C therapy with sofosbuvir-based regimens after liver transplantation. Open-label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT- 450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adult Liver Transplant Recipients with Genotype 1 Hepatitis C Virus (HCV) Infection. A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects with Liver Cirrhosis. Site Principal Investigator. A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Non-Genotype 1 HCV Infection. A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Genotype 1 HCV Infection (GS-US-367-1168). A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead- Sponsored Trials in Subjects with Chronic Hepatitis C Infection. TOPAZ II: An Open-Label, Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.
What made you decide to work in transplantation?: 
Transplantation represents an opportunity for a renewal of life. It is both gratifying and humbling to be part of the team that can change the trajectory of a serious illness, and turn what could have been the end to a new beginning. Seeing a patient receive a second chance at life is the best reward that I can get for all my efforts. In addition, transplantation is always at the cutting edge of medicine, where generating innovations and thinking outside the box is almost in the daily routine. It is both stimulating and fulfilling to belong to the community that emits a constant spark to advance the field forward.
What do you find to be the most valuable aspect of your work?: 
Teamwork is the most valuable component of my work. It would be impossible for me to provide the appropriate comprehensive care for a liver transplant candidate or recipient as a single provider. I am highly appreciative of my colleagues who provide valuable input into the multidisciplinary management of our patients, and I greatly value the contribution that each member of our transplant team makes to provide exemplary and personalized care to our patients.
Fun Facts: 

I am the oldest of six daughters (thankfully, the attempts to have a son stopped after the sixth daughter). Half of my family is here in the United States, and the other half remains in the Philippines, so our family reunions tend to take place somewhere in between.